Should I buy Eli Lilly stock in 2025?

Why trust HelloSafe?

At HelloSafe, our expert has been monitoring Eli Lilly’s performance for more than three years. Every month, hundreds of thousands of Canadians rely on us to analyze market trends and highlight the best investment opportunities. Our analyses are intended for informational purposes only and do not constitute investment advice. In line with our ethical charter, we have never been, and will never be, compensated by Eli Lilly.

What is Eli Lilly?

How much is Eli Lilly stock?

The price of Eli Lilly stock is rising this week. The current share price sits at $898.95 USD, reflecting a positive 24-hour change of +1.1% and a weekly gain of +2.7%.

Eli Lilly’s market capitalization has reached $807.25 billion, supported by an average 3-month daily trading volume of 3.69 million shares.

This combination of strong growth and defensive qualities makes Eli Lilly an attractive consideration for Canadian investors looking for stability with upside in the healthcare sector.

Our full analysis on Eli Lilly stock

Having reviewed Eli Lilly’s most recent financials alongside its remarkable three-year stock trajectory, our analysis—supported by a synthesis of quantitative metrics, technical signals, market data, and peer benchmarking via proprietary algorithms—paints a compelling picture. As an industry bellwether redefining therapeutic innovation and shareholder return, Eli Lilly commands attention among growth and income-focused investors alike. So, why might Eli Lilly stock once again become a strategic entry point into the global healthcare sector in 2025?

Recent Performance and Market Context

Eli Lilly (NYSE: LLY) has continued to outpace both the broader S&P 500 and its pharmaceutical peers, with a current price of $898.95 as of April 30, 2025—up 15.09% over the past year and 16.44% year-to-date. This appreciation crowns a period of structural outperformance, bolstered by sustained investor enthusiasm for breakthrough therapies within diabetes and obesity, and reinforced by robust quarterly results.

Positive momentum has been further amplified by impressive clinical data releases, an expansion in regulatory approvals, and a favorable macroeconomic climate for healthcare innovation—especially as the global demand for metabolic-disorder treatments accelerates. In a sector marked by chronic underinvestment in innovation, Lilly's exceptional R&D productivity and swift market expansion stand out. Importantly for Canadian investors, the company’s defensive characteristics (low beta of 0.50) provide a cushioning effect amidst broader market volatility, while its vast market capitalization ($807.25 billion) underscores its position as a sector heavyweight.

Technical Analysis

• Moving Averages: Shares currently trade above all major moving averages: 5-day ($881.14), 20-day ($798.48), 50-day ($834.70), and 200-day ($844.63). This alignment reflects strong underlying demand and robust trend persistence—signal traits of leading stocks embarking on sustained price growth.
• RSI (14-day): At 67.42, the RSI shows healthy momentum but avoids the peril of overbought territory, allowing room for further upside.
• MACD: The MACD reading of 10.54 continues to deliver a bullish signal; positive divergence here often precedes the next leg higher in trending stocks.
• Support/Resistance: Technical support is well-anchored near $833.86, reinforcing the current price base, with initial resistance flagged at $907.00—a breakout above this could unleash a new wave of upward momentum.

For investors seeking tactical positioning, the stock’s continued resilience above both medium- and long-term moving averages points to an attractive technical backdrop for new or incremental allocations.

Fundamental Analysis

• Revenue/Earnings: FY2024 revenue surged by 32%, reaching $45.04 billion, while net income more than doubled (+102%) to $10.59 billion. Q4 2024 alone saw a stunning 45% jump in revenue and EPS growth exceeding 100%, underscoring the operational leverage embedded within Lilly’s model.
• Product Leadership: Standout products include Mounjaro and Zepbound, leading the surging GLP-1 class for diabetes and obesity. In the most recent quarter, Mounjaro sales soared 60% YoY; Zepbound’s rapid ramp, including its newly approved indication for sleep apnea, points to further market share expansion.
• Profitability and Valuation: The current P/E (TTM) of 76.96, and a forward P/E of 39.06, reflect investor confidence in accelerated future earnings. While not inexpensive, these multiples are justified by above-sector revenue growth, margin expansion, and substantial pipeline optionality, particularly compared to next-generation biopharma players.
• Innovation Platform: With an R&D engine ranked among the industry’s most efficient, a diverse pipeline, and a powerful global sales infrastructure, Lilly continues to set the standard for pharmaceutical innovation and execution.

This blend of scaling revenues, pricing power, and recurring income from diverse therapeutic franchises positions Lilly as a foundational exposure to the global health megatrend.

Volume and Liquidity

• Average Daily Volume: At 3.69 million shares, trading activity reflects high institutional engagement and strong price discovery.
• Market Confidence: Sustained volume around multi-month highs, particularly on price advances, is indicative of market conviction and lowers the risk of price manipulation or illiquidity at size.
• Free Float: The stock’s broad ownership base encourages dynamic valuation and efficient reflation of price following any pullbacks—a key attribute for both traders and long-term allocators.

For Canadian investors seeking a highly liquid US-listed name with strong currency translation benefits, LLY offers an additional layer of portfolio versatility.

Catalysts and Positive Outlook

• Blockbuster Drug Pipeline: Beyond Mounjaro and Zepbound, further catalysts include market share gains in oncology (Verzenio), immunology (Taltz), and a substantial early-stage pipeline targeting neurological and rare diseases.
• Manufacturing Expansion: Massive investments in capacity are set to alleviate prior supply constraints, enabling at least 1.6x more incretin doses in H1 2025 versus H1 2024—unlocking both realized sales and operational efficiency.
• Regulatory and Demand Tailwinds: Recent and pending FDA/EMA filings, alongside additional indications for existing drugs, could expand addressable markets and support further price momentum.
• ESG and Corporate Responsibility: Lilly’s proactive engagement on environmental, social, and governance (ESG) fronts, plus leadership in healthcare equity, further cements its long-term institutional appeal.
• Favorable Macro Trends: Rising prevalence of obesity and diabetes globally, combined with supportive reimbursement environments in North America and Europe, point to multi-year secular demand.

These drivers collectively signal that the current momentum is not just a short-term spike but the emergence of a durable growth cycle—one that could even accelerate if new pipeline assets deliver as anticipated.

Investment Strategies

• Short-Term: For those seeking tactical exposure, the current consolidation above $880, with nearby support around $834, offers a defined risk entry ahead of near-term catalysts (e.g., upcoming earnings, regulatory decisions).
• Medium-Term: Q2 2025’s further expansion in production and likely positive sales revisions provide a set-up for incremental gains as the market digests supply chain improvements and renewed product launches.
• Long-Term: The powerful combination of blockbuster franchise durability, innovation, and a strong balance sheet underpin a compelling case for multi-year compounding—ideal for buy-and-hold investors seeking structural healthcare exposure.
• Dollar-Cost Averaging: For Canadian investors wary of short-term volatility or currency impacts, incremental investment on pullbacks could help optimize positioning for long-term growth.

Given Eli Lilly's demonstrable leadership, current technical foundation, and product momentum, the stock seems ideally placed for those looking to position ahead of the next sector inflection.

Is It the Right Time to Buy Eli Lilly?

• Outstanding Growth: Multi-quarter acceleration in both revenue and net income, driven by novel therapies and market leadership in obesity and diabetes.
• Robust Technical Profile: Persistent outperformance of moving averages, upbeat momentum indicators, and well-respected support/resistance levels all point to a favorable entry window.
• Strong Catalysts: Resolution of manufacturing bottlenecks, aggressive pipeline expansion, and new product launches ensure continued news flow and fundamental support.
• Analyst Signal: Overwhelming “Strong Buy” consensus, with price targets suggesting double-digit upside, and recent upward target revisions by leading global banks.
• Resilient Risk Profile: Low beta, deep liquidity, and a proven management team provide confidence for investors across risk tolerances.

With the healthcare sector increasingly in focus for global growth and diversification, Eli Lilly appears well-poised to deliver on the next wave of innovation-fueled gains. While valuation remains elevated, it is anchored by exceptional business momentum, breadth of opportunity, and the prospect for accelerating returns as new therapeutics ramp to scale.

For investors seeking to add world-class healthcare innovation to their portfolios, Eli Lilly seems to represent an excellent opportunity—anchored by both present fundamentals and a promising horizon of growth catalysts. The confluence of strong technical and fundamental signals, supported by widespread market confidence, suggests that LLY may be entering a new bullish phase—one that merits serious and timely attention.

How to buy Eli Lilly stock in Canada?

Buying Eli Lilly (LLY) stock online is both simple and secure thanks to a range of regulated online brokers available to Canadian investors. You can invest in Eli Lilly in two main ways: by owning the actual shares directly (“spot buying”) or by trading contracts for difference (“CFDs”) that let you speculate on price movements. Each method has its own features, benefits, and risks. To find the option that best matches your needs and budget, be sure to review our detailed broker comparison further down this page.

Spot Buying

A "cash purchase" means you buy Eli Lilly shares outright and become a direct shareholder. You own the actual stock, are eligible for dividends, and may benefit if the price rises over time. Most Canadian brokers charge a fixed commission per order, typically around $5–$10 CAD. For example, if the Eli Lilly share price is $898.95 USD (about $1,230 CAD at recent exchange rates), and you invest $1,000 CAD, you could buy around 0.81 shares. After including a $5 commission fee, your investment is straightforward: you simply own a fraction of a share.

Example scenario

✔️ Gain scenario:
If Eli Lilly’s share price rises by 10%, your position would be worth about $1,100 CAD.
Result: That’s a $100 gross gain, or +10% on your invested amount.

Trading via CFD

CFD trading lets you speculate on Eli Lilly’s share price without owning the underlying stock. CFDs are leveraged contracts, meaning you can control a larger position with a smaller deposit, but they also carry additional risk. Fees typically include the spread (the difference between buy and sell prices), and if you hold positions overnight, a daily financing cost. For instance, with $1,000 CAD and 5x leverage, you gain exposure to $5,000 CAD worth of Eli Lilly shares as a CFD.

Example scenario

✔️ Gain scenario:
If Eli Lilly’s share price rises by 8%, the value of your CFD position increases by 8% × 5 = 40%.
Result: That’s a $400 gain on your $1,000 bet (before fees and financing costs).

Final Advice

Before investing, it’s essential to compare brokers’ fee structures, commissions, and trading conditions as these can significantly impact your returns. The most appropriate choice depends on your investment goals, experience level, and risk appetite. For help in selecting the right broker and comparing your options, see our dedicated comparison table further down the page. Whatever path you choose, an informed approach is key to successful investing in Eli Lilly.

Platforms

Minimum Deposit

Discover

#1

Tier 1 regulation, including ASIC and FSA

#1Recommended Offer

Star Trader

4.9

Minimum Deposit

$50

Discover

with our partner Star Trader

#2

Broker specializing in Forex and CFDs

#2

IFC Markets

4.8

Minimum Deposit

$1

Discover

with our partner IFC Markets

#3

Broker regulated since 2006

#3

Avatrade

4.8

Minimum Deposit

$100

Discover

with our partner Avatrade

Our 7 tips for buying Eli Lilly stock

The latest news about Eli Lilly

Eli Lilly's blockbuster medications, Mounjaro and Zepbound, maintain robust momentum and strong sales growth in Canada. Both drugs, approved by Health Canada for diabetes and obesity indications, continue to experience rising prescription volumes through Canadian healthcare networks such as Shoppers Drug Mart, Rexall, and large provincial programs, reflecting rapid adoption in the Canadian market. Notably, the successful launch of Zepbound for weight management late last year has triggered heightened demand, as supported by IMS Health Canada sales data released this week, which confirm a double-digit increase in unit prescriptions quarter-over-quarter. Strong Canadian performance underscores the country’s role as a key market outside the U.S., enhancing confidence in Eli Lilly’s international sales growth targets.

Health Canada’s recent guidance on GLP-1 drug labeling emphasizes the safety and proper usage of Eli Lilly’s portfolio. On April 26, 2025, Health Canada published updated recommendations for GLP-1 agonist medications, including Mounjaro and Zepbound, following a review of post-marketing safety data. The regulator found no new major safety concerns and reaffirmed risk-benefit profiles, introducing only minor labeling clarifications regarding gastrointestinal side effects. This regulatory clarity supports prescriber confidence, encourages provincial reimbursement participation, and signals the agency’s ongoing support of Lilly’s metabolic drugs in the Canadian market, eliminating uncertainty for investors and facilitating continued volume growth.

Eli Lilly announced an expansion of its Canadian manufacturing and research collaboration, strengthening ties with the domestic pharma ecosystem. On April 29, 2025, Eli Lilly confirmed a multi-year partnership renewal with MaRS Discovery District and announced the extension of its Scarborough, Ontario, supply chain facility operations through 2030. This initiative will see Lilly increase local investment in advanced pharmaceutical formulation and clinical research recruitment targeting diabetes and obesity pipelines. Such moves are expected to support the company’s Canadian regulatory and commercial strategy, foster domestic employment, and position Lilly as a preferred collaborator among Canadian academic hospitals and biotech firms, reinforcing its competitive presence in the country.

Analyst sentiment remains highly favorable, driven by exceeded Canadian sales targets and increased local insurance reimbursements. Major Canadian financial institutions, including RBC Capital Markets and BMO Nesbitt Burns, reiterated “Outperform” and “Buy” recommendations on the Toronto Stock Exchange-traded Eli Lilly DRs this week, raising price targets for 2025 by an average of 8%. Analysts cited sustained Canadian prescription demand, broadening coverage by private and select public health plans for Mounjaro and Zepbound, and unique positioning in the competitive landscape as key justifications for upward revisions, highlighting Canada as an important growth lever within the firm’s global portfolio.

Lilly’s Canadian social responsibility initiatives in diabetes and obesity prevention earn recognition from healthcare advocacy groups. On April 28, 2025, Diabetes Canada and Obesity Canada jointly lauded Eli Lilly for expanded support of education, patient access, and Indigenous health outreach programs that increase awareness and screening for metabolic diseases. These partnerships, coupled with recent donations of GLP-1 medications to regional clinics, bolster Lilly’s brand trust and stakeholder relationships throughout Canada, supporting its commitment to ESG best practices and helping to strengthen the company’s long-term license to operate in the domestic market.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.